INDUCING IMMUNOGENIC CELL DEATH AND ANTITUMOR ACTIVITY IN RESPONSE TO RADIOIMMUNOTHERAPY

Denis Beckford*, Jason Li, Caroline Jennings, Megan McCluskey, Le-Cun Xu, Debbie Lewis, Patrik Brodin, Amanda Chin, Monideepa Roy, Mary Chen, Helen Kotanides. Actinium Pharmaceuticals, Inc, New York, NY, USA

Background Conventional cancer therapies, such as chemotherapy and external beam radiation therapy, are known to induce the release of damage-associated molecular patterns (DAMPs) that stimulate an antitumor immune response. Radioimmunotherapy (RIT) offers a unique opportunity by delivering cytotoxic energy specifically to target-expressing cancer cells. However, the immunomodulatory properties of RIT are not well characterized. Hence, we hypothesized that tumor cell cytotoxicity induced by radiolabeled antibodies (ARCs) can activate an immune response by releasing DAMPs. Herein we investigated the effects of alpha or beta emitting ARCs (225Ac and 177Lu) on DAMP induction and engagement of the innate immune response in vitro. Furthermore, we evaluated the antitumor effects of 225 Ac and 177 Lu ARCs in vivo.

Methods 225 Ac or 177 Lu ARCs (CD33, HER2 and HER3) were prepared using p-Bn-SCN-DOTA. ARCs were evaluated for target-binding using human recombinant proteins and receptor positive tumor cell lines. The cytotoxic effect of ARCs was determined by XTT, flow cytometry and clonogenic assays. DAMP induction was investigated in cells treated with 225 Ac or 177 Lu ARCs and levels of CRT, HSP70, and HMGB1 were measured by flow cytometry and ATP concentrations determined by ELISA. The influence of ARC treatment on the innate immune response was evaluated by flow cytometry. The antitumor effects of 225 Ac or 177 Lu ARCs was examined in mice bearing human NCI-H1975 NSCLC xenograft tumors.

Results The 225 Ac and 177 Lu ARCs showed cytotoxicity and inhibited colony formation in target expressing cancer cells in vitro. DAMP levels in 225 Ac ARC treated cells was induced, including CRT translocation to cell surface, increased ATP release and HSP70 upregulation. Furthermore, an enhanced innate immune response was observed following 225 Ac ARC treatment. Contrastingly, treatment with 177 Lu ARCs did not show significant DAMP induction compared to untreated cells in the dose ranges studied. However, the efficacy study testing 225 Ac and 177 Lu ARCs in mouse xenograft model of NSCLC revealed that both ARCs had similar antitumor efficacy in vivo.

Conclusions The observations from this study suggest that 225 Ac radionuclide-based ARCs as part of their mechanism of action can induce immunogenic cell death by the release of DAMPs whereas beta radionuclides such as 177 Lu may utilize different damage response pathways. These findings could be explained by DNA double stranded breaks caused by alpha radiation. Importantly, both 225 Ac and 177 Lu ARCs showed in vivo antitumor activity that warrants their further evaluation as warheads for RIT.